By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Oxford Gene Technology today announced a licensing deal covering 12 colorectal cancer tissue biomarkers.

The exclusive license from Inven2, the technology transfer office at Oslo University Hospital, and the University of Oslo allows OGT to commercialize any test developed from the biomarkers and to sublicense the markers to other parties, OGT said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.